These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29162646)

  • 1. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
    Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
    Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
    [No Abstract]   [Full Text] [Related]  

  • 2. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
    Nabors LB; Lamb LS; Goswami T; Rochlin K; Youngblood SL
    Front Immunol; 2024; 15():1299044. PubMed ID: 38384458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
    Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
    Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional control of O
    Happold C; Stojcheva N; Silginer M; Weiss T; Roth P; Reifenberger G; Weller M
    J Neurochem; 2018 Mar; 144(6):780-790. PubMed ID: 29480969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
    Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
    PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
    J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma.
    Liu D; Cheng Y; Qiao S; Liu M; Ji Q; Zhang BL; Mei QB; Zhou S
    ACS Nano; 2022 May; 16(5):7409-7427. PubMed ID: 35549164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
    Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
    Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 17. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
    Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
    Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.